Medical Council of Canada MCCQE - Medical Council of Canada Qualifying Examination Part 1 Exam

Comprehensive and Detailed Explanation:

This patient is likely experiencing extrapyramidal symptoms (dysphagia/dystonia) due to haloperidol. Switching to an atypical antipsychotic (like quetiapine), which has a lower risk of EPS, is appropriate. Dysphagia in the context of antipsychotic use requires prompt medication review.

Toronto Notes 2023 – Psychiatry, “Antipsychotics and Extrapyramidal Effects”:

“Dysphagia can be a sign of extrapyramidal side effects. Consider switching to an atypical antipsychotic with lower EPS risk.”

MCCQE1 Objectives (Psychiatry > 71-5: Antipsychotic Adverse Effects):

“Candidates must recognize and manage EPS, including drug-induced dysphagia.”

Dantrolene (C) is for neuroleptic malignant syndrome, not isolated dysphagia. Laryngoscopy (B) may be useful later but not first-line. Reassurance (D) is unsafe. Lorazepam (E) may help in dystonia but doesn ' t address the root cause.

Comprehensive and Detailed Explanation:

Complex endometrial hyperplasia with atypia carries a high risk of progression to or concurrent endometrial carcinoma. Definitive management in postmenopausal women is total hysterectomy with bilateral salpingo-oophorectomy.

Toronto Notes 2023 – Gynecology, Abnormal Uterine Bleeding:

“Endometrial hyperplasia with atypia in postmenopausal women is best managed surgically due to the risk of malignancy.”

MCCQE1 Objectives – Gynecology > Postmenopausal Bleeding:

“Candidates should identify endometrial hyperplasia with atypia as an indication for hysterectomy in appropriate patients.”

Ablation (A) is contraindicated. Progesterone (B) is used for non-atypical hyperplasia. D & C (C) and hysteroscopy (D) are diagnostic but not definitive.

====================================================

Once the patient’s confusion has resolved, he should be presumed capable unless an assessment shows otherwise. MCCQE ethics objectives prioritize patient autonomy, informed decision-making, and confidentiality . Families may request “therapeutic privilege” or nondisclosure, but this is not the default and cannot override a capable patient’s right to information needed to make decisions. The appropriate first step is to explore the patient’s preferences about receiving serious news (some patients prefer limited information or to delegate decisions). Asking the patient whether he wants to know the diagnosis respects autonomy while remaining sensitive to potential distress. Simply telling him immediately (without checking preferences) may conflict with patient-centered disclosure, and automatically complying with the family’s request violates the patient’s rights and undermines informed consent for goals-of-care planning. A palliative care consult is appropriate, but only after clarifying the patient’s understanding and wishes and beginning honest, preference-guided communication. The clinician should also support the family, explain ethical duties, and reassure them that disclosure can be done gradually and compassionately.

This patient has life-threatening complications of missed dialysis , including severe hyperkalemia (K⁺ 7.1 mmol/L), metabolic acidosis (HCO₃⁻ 11 mmol/L), volume overload with pulmonary edema (hypoxia, crackles, elevated JVP), and altered mental status. MCCQE objectives emphasize immediate recognition and treatment of emergent indications for dialysis (AEIOU: Acidosis, Electrolyte abnormalities, Intoxication, Overload, Uremia) . This patient meets multiple criteria—particularly refractory hyperkalemia and pulmonary edema—requiring urgent hemodialysis .

In emergencies where delay would risk death or serious harm, treatment proceeds under implied consent , even if the patient is confused and capacity is uncertain. Contacting family or psychiatry would dangerously delay life-saving care. While temporizing measures (e.g., IV calcium, insulin/glucose) may be given, definitive management is emergent dialysis. Morphine and furosemide alone are inadequate in severe renal failure with life-threatening hyperkalemia. Therefore, immediate initiation of urgent dialysis is the correct next step.

Magnesium sulfate toxicity is dose-dependent. The earliest and most sensitive clinical sign is the loss of deep tendon reflexes (especially patellar), which occurs before respiratory depression or cardiac changes.

Toronto Notes 2023 – Obstetrics Chapter:

“Toxicity from magnesium sulfate is progressive and typically presents first with loss of deep tendon reflexes. Respiratory depression and cardiac arrest occur at higher serum levels. Regular monitoring of reflexes, respiratory rate, and urine output is essential.”

MCCQE1 Objectives (Obstetrics > 83-3: Preterm Labour and Tocolysis):

“The candidate must recognize early signs of magnesium sulfate toxicity including areflexia and respiratory depression.”

Tachycardia (B), hypotension (C), and tachypnea (D) are not typical early signs. Oliguria (E) may be a risk factor for accumulation but is not the first sign of toxicity.

The presentation is consistent with cervical spondylosis — a degenerative condition. In the absence of neurologic findings, further imaging beyond plain radiography is not warranted. Management includes conservative measures such as physiotherapy and analgesia.

Toronto Notes 2023 – Rheumatology, Cervical Spondylosis:

“Patients with typical cervical spondylosis and no red flags (e.g., neurologic deficits) do not require MRI. Treatment is conservative. Radiographs showing disc space narrowing and osteophytes confirm diagnosis.”

MCCQE1 Objectives – Internal Medicine > Musculoskeletal Disorders:

“Candidates must recognize typical degenerative spine disorders and avoid unnecessary investigations when clinical findings are straightforward.”

MRI (B) is useful if myelopathy or radiculopathy is suspected. CT (A), EMG (C), and LP (D) are not indicated here.

====================================================

Patients with developmental disabilities must still be engaged directly unless clearly incapable. It is vital to first establish the companion’s relationship to the patient and give the patient the opportunity to communicate.

Toronto Notes 2023 – ELOM, Consent and Capacity:

“Presume capacity in adults with developmental disabilities unless proven otherwise. Direct communication with the patient is essential, and the identity of accompanying individuals should be clarified.”

MCCQE1 Objectives – ELOM > Patient Autonomy and Consent:

“Candidates must respect patient autonomy and include developmentally delayed individuals in medical discussions unless incapacity is determined.”

Options A and C delay establishing capacity and relationship. Option D is premature. Option E bypasses consent and interaction with the patient.

The levonorgestrel-releasing intrauterine system (LNG-IUS) is the first-line treatment for heavy menstrual bleeding, particularly in women with risk factors for endometrial hyperplasia and contraindications to systemic hormones (e.g., morbid obesity, diabetes, OSA).

Toronto Notes 2023 – Gynecology, “Abnormal Uterine Bleeding” Section:

“The LNG-IUS is highly effective in reducing menstrual bleeding and improving hemoglobin levels. It is particularly recommended in women with obesity, chronic anovulation, or contraindications to estrogen.”

MCCQE1 Objectives (Obstetrics and Gynecology > 82-1: Abnormal Uterine Bleeding):

“Candidates must consider the LNG-IUS as a preferred non-surgical treatment for chronic heavy menstrual bleeding when endometrial pathology has been excluded.”

Oral contraceptives (C) are not first-line in morbid obesity due to increased thromboembolic risk. Cyclic medroxyprogesterone (D) is less effective than LNG-IUS. Hysterectomy (A) is definitive but should follow failure of conservative therapy.

Valproic acid is well known to cause thrombocytopenia, especially at higher serum concentrations or in patients over 60. Bruising with platelet count < 100 × 10⁹/L is a classic manifestation.

Toronto Notes 2023 – Psychiatry, Mood Disorders & Pharmacology Section:

“Valproic acid is associated with hematologic side effects including thrombocytopenia. Platelet counts should be monitored regularly.”

MCCQE1 Objectives – Psychiatry > Pharmacotherapy:

“The candidate must recognize adverse effects of mood stabilizers including hematologic complications of valproic acid.”

Other listed medications (A–D) have no common or direct link with thrombocytopenia in this context.

Comprehensive and Detailed Explanation:

This patient has stress urinary incontinence and an incidental cystocele. First-line management of mild pelvic organ prolapse and stress incontinence includes pelvic floor physiotherapy (e.g., Kegel exercises). Surgical options are reserved for severe or refractory cases.

Toronto Notes 2023 – Gynecology, Pelvic Floor Disorders:

“For asymptomatic prolapse or mild stress incontinence, recommend pelvic floor strengthening. Conservative management is preferred before surgical referral.”

MCCQE1 Objectives – Gynecology > Urogynecology:

“Candidates should initiate pelvic floor therapy in women with mild prolapse or urinary leakage prior to specialist referral.”

Topical estrogen (B) helps with atrophic vaginitis, not stress incontinence. Hysterectomy (A) and specialist referral (C) are premature. Avoiding impact sports (E) is not a treatment.

====================================================